Want to see IN:ASTRAZEN full AI Analyst Report?
AstraZeneca Pharma India Limited (ASTRAZEN) AI Stock Analysis
AstraZeneca Pharma India Limited
(NSE:ASTRAZEN)
The overall score is heavily pressured by extremely bearish technicals and a stretched valuation. While the balance sheet is solid and income growth is strong, the alarming deterioration in cash flow and gross margins significantly undermines financial quality. The stock's deep downtrend and oversold signals present substantial near-term risk.
AstraZeneca Pharma India Limited (ASTRAZEN) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 162.63B
- Dividend Yield
- 0.57%
- Average Volume (3M)
- 548
- Price to Earnings (P/E)
- 93.8
- Beta (1Y)
- 0.84
- Revenue Growth
- 31.10%
- EPS Growth
- -7.49%
- Country
- India
- Employees
- 760
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
AstraZeneca Pharma India Limited Business Overview & Revenue Model
Company Description
AstraZeneca Pharma India Limited operates as a biopharmaceutical entity, engaged in the development, production, and global commercialization of pharmaceutical products, serving both the Indian domestic market and international clientele. The company...
How the Company Makes Money
AstraZeneca Pharma India Limited primarily makes money by selling prescription pharmaceutical products in India. Its key revenue stream is domestic sales of branded medicines from its therapeutic portfolio (notably in specialty care areas such as onc...
AstraZeneca Pharma India Limited Financial Statement Overview
Summary
Strong revenue growth (+13.6%) and net income surge (+62%) are offset by a sharp gross margin contraction (26.5% from 41.6%) and critically weak cash flow generation. Operating cash flow plummeted to INR 68M, covering only 0.7% of debt, raising sustainability concerns.
Income Statement
72PositiveBalance Sheet
86Very PositiveCash Flow
35Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.32B | 22.76B | 17.13B | 12.96B | 10.03B | 8.06B |
| Gross Profit | 7.64B | 6.02B | 7.13B | 6.22B | 5.78B | 4.48B |
| EBITDA | 2.42B | 2.85B | 1.98B | 2.36B | 1.51B | 1.01B |
| Net Income | 1.70B | 1.88B | 1.16B | 1.62B | 992.90M | 616.00M |
Balance Sheet | ||||||
| Total Assets | 0 | 19.89B | 15.18B | 10.78B | 9.85B | 8.57B |
| Cash, Cash Equivalents and Short-Term Investments | 4.48B | 4.49B | 5.53B | 5.06B | 5.00B | 4.48B |
| Total Debt | 0 | 1.11B | 357.30M | 45.90M | 72.10M | 86.30M |
| Total Liabilities | -8.73B | 11.16B | 7.48B | 3.66B | 3.96B | 3.45B |
| Stockholders Equity | 8.73B | 8.73B | 7.70B | 7.12B | 5.89B | 5.11B |
Cash Flow | ||||||
| Free Cash Flow | -660.20M | 32.10M | 636.10M | 171.10M | 497.70M | 911.80M |
| Operating Cash Flow | -657.30M | 68.20M | 653.60M | 278.70M | 582.90M | 1.01B |
| Investing Cash Flow | 135.40M | -33.40M | 308.00M | 217.40M | 181.10M | 47.40M |
| Financing Cash Flow | -845.60M | -919.00M | -655.90M | -443.80M | -244.80M | -94.60M |
AstraZeneca Pharma India Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTRAZEN, the sentiment is Negative. The current price of 6367.35 is above the 20-day moving average (MA) of 6013.79, below the 50-day MA of 6522.57, and below the 200-day MA of 7893.57, indicating a neutral trend. The MACD of -80.23 indicates Negative momentum. The RSI at 56.64 is Neutral, neither overbought nor oversold. The STOCH value of 84.12 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTRAZEN.
AstraZeneca Pharma India Limited Peers Comparison
Overall Rating
IN:GLENMARK79Outperform
IN:LUPIN77Outperform
IN:TORNTPHARM69Neutral
IN:SUNPHARMA64Neutral
IN:DRREDDY63Neutral- IN:ASTRAZEN52Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:GLENMARK | 79Outperform | INR 651.37B | 36.08 | ― | 0.22% | 32.94% | 138.54% |
| IN:LUPIN | 77Outperform | INR 918.70B | 16.62 | ― | 0.90% | 28.19% | 49.25% |
| IN:TORNTPHARM | 69Neutral | INR 1.76T | 75.58 | ― | 0.32% | 42.06% | -3.48% |
| IN:SUNPHARMA | 64Neutral | INR 4.27T | 35.26 | ― | 0.90% | 12.13% | 4.94% |
| IN:DRREDDY | 63Neutral | INR 1.13T | 40.24 | ― | 0.59% | -3.60% | -52.23% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IN:ASTRAZEN | 52Neutral | INR 159.18B | 93.80 | ― | 0.57% | 31.10% | -7.49% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:ASTRAZEN | AstraZeneca Pharma India Limited | 6367.35 | -3177.69 | -33.29% | |
| IN:DRREDDY | Dr. Reddy's Laboratories Ltd. | 1350.20 | 156.97 | 13.15% | |
| IN:GLENMARK | Glenmark Pharmaceuticals Limited | 2308.00 | 463.18 | 25.11% | |
| IN:LUPIN | Lupin Limited | 2009.00 | 25.24 | 1.27% | |
| IN:SUNPHARMA | Sun Pharmaceutical Industries Limited | 1778.25 | 100.82 | 6.01% | |
| IN:TORNTPHARM | Torrent Pharmaceuticals Ltd | 4635.15 | 1089.70 | 30.74% |
AstraZeneca Pharma India Limited Corporate Events
Delhi High Court Restrains NPPA Action Against AstraZeneca
AstraZeneca Pharma India Limited operates in the pharmaceutical industry and markets prescription medicines in India, including respiratory inhalation therapies such as Symbicort Turbuhaler. Its portfolio serves healthcare providers and patients in t...
AstraZeneca Pharma India Confirms SEBI Dematerialization Compliance for Q2 FY2026
AstraZeneca Pharma India Limited has submitted a certificate to BSE and NSE confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate, issued by...
Delhi High Court Grants AstraZeneca India Interim Relief in NPPA Drug Pricing Dispute
AstraZeneca Pharma India Limited has informed the stock exchanges that the Delhi High Court has granted an interim stay on a National Pharmaceutical Pricing Authority demand notice alleging overcharging on Betaloc-50 tablets. The notice claimed the c...
AstraZeneca Pharma India Discloses Unsolicited ESG Rating from Crisil
AstraZeneca Pharma India Limited disclosed that Crisil ESG Ratings & Analytics has assigned it an Environmental, Social and Governance score of 57, based solely on publicly available information. The company clarified it did not engage Crisil for...
AstraZeneca Pharma India Plans Virtual Meeting With Institutional Investor
AstraZeneca Pharma India Limited has scheduled a virtual one-on-one meeting with an institutional investor on August 26, 2026, in line with regulatory requirements for disclosure of analyst and investor interactions. The company notes that the date m...
AstraZeneca Pharma India Schedules Virtual Meet with Institutional Investor
AstraZeneca Pharma India has announced that it will hold a virtual one-on-one meeting with an institutional investor on August 19, 2026, as part of its ongoing engagement with the analyst and investor community. The company noted that the schedule ma...
AstraZeneca Pharma India Clears Dividend and Board Moves at 47th AGM
AstraZeneca Pharma India Limited held its 47th Annual General Meeting on August 10, 2026 via video conferencing, after a brief delay due to lack of quorum. Shareholders considered routine corporate matters, including adoption of the FY 2026 financial...
AstraZeneca Pharma India posts 30% revenue surge in Q1 FY2026–27 driven by core therapies
AstraZeneca Pharma India reported a strong start to FY2026–27, with total revenue from operations rising 30% year-on-year to INR 6,828 million in the quarter ended June 30, 2026. The growth was driven by robust performance across its core thera...
AstraZeneca Pharma India Wins New Breast Cancer Approval for Enhertu
AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization to import Trastuzumab Deruxtecan 100mg/5mL, marketed as Enhertu, for an additional indication in India. The approval covers adjuvant treatme...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 28, 2026